Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...
In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated ...
FreeDM2 randomized controlled trial shows Libre technology helps people with type 2 diabetes on basal insulin improve glucose management: Abbott Park, Illinois Saturday, March 14, ...
Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...
Crescel LLC, an innovative science and technology company, today announced results from a double-blind, randomized, active comparator-controlled clinical trial evaluating its biobotanical Skin Renewal ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
When a randomized evaluation finds null results, it is important to understand why. We investigated two very different explanations for the finding from a randomized evaluation that the Camden ...
Morning Overview on MSN
Eli Lilly says retatrutide met goals in its first phase 3 diabetes trial
Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results